Phase I trial of fractionated-dose 177Lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC) Meeting Abstract


Authors: Tagawa, S. T.; Akhtar, N. H.; Nikolopoulou, A.; Vallabhajosula, S.; Osborne, J.; Beltran, H.; Kahn, R.; Goldsmith, S. J.; Nanus, D. M.; Bander, N. H.
Abstract Title: Phase I trial of fractionated-dose 177Lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC)
Meeting Title: 17th European Cancer Conference (ECCO 17)
Journal Title: European Journal of Cancer
Volume: 49
Issue: Suppl. 2
Meeting Dates: 2013 Sep 27-Oct 1
Meeting Location: Amsterdam, Netherlands
ISSN: 0959-8049
Publisher: Elsevier Inc.  
Date Published: 2013-09-01
Start Page: S701
End Page: S702
Language: English
ACCESSION: WOS:000326843604277
PROVIDER: wos
DOI: 10.1016/S0959-8049(13)70064-9
Notes: Meeting Abstract: 2915 -- 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity -- SEP 27-OCT 01, 2013 -- Amsterdam, NETHERLANDS -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph R Osborne
    61 Osborne